Compare Virgin Galactic Holdings, Inc. (SPCE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs BIO-TECHNE Corp — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.98 (market cap $474.50M), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is far larger — about 23.9× Virgin Galactic Holdings, Inc.'s market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| SPCE | TECH | |
|---|---|---|
Market Cap | $474.50M | $11.34B |
Sector | Industrials | Health |
52-Week High | $7.52 | $72.48 |
52-Week Low | $2.17 | $43.31 |
Enterprise Value | $438.48M | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Virgin Galactic (SPCE) trades at $3.13, up 2.96% with a bullish technical outlook from moving averages. The company continues to report significant losses with negative profit margins and cash flow, though recent quarters have shown earnings beats. Management targets positive cash flow by 2027, but commercial spaceflight delays to February 2027 create execution risk. Analyst sentiment is divided with 29% buy, 41% hold, and 29% sell ratings.
SPCE represents a high-risk, speculative opportunity in the emerging space tourism sector. The path to profitability remains distant with substantial cash burn, though strong ticket demand provides potential upside if execution improves. Key risks include ongoing dilution, high short interest, and the capital-intensive nature of space operations. Investors should weigh the long-term potential against persistent financial challenges.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
